(Q51364519)

English

Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study.

scientific article published on 2 December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22134839

Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. (English)

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22134839

type 2 diabetes

0 references

author name string

C Beysen

1

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22134839

E J Murphy

2

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22134839

K Deines

3

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22134839

M Chan

4

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22134839

E Tsang

5

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22134839

A Glass

6

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22134839

S M Turner

7

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22134839

J Protasio

8

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22134839

T Riiff

9

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22134839

M K Hellerstein

10

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22134839

publication date

2 December 2011

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22134839

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22134839

55

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22134839

432-442

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22134839

2

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22134839

https://scigraph.springernature.com/pub.10.1007/s00125-011-2382-3

0 references

Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Effect of colestimide on absorption of unconjugated bile acids in the rat jejunum

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptor alpha-controlled metabolic pathways in mice.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Role of bile acids and bile acid receptors in metabolic regulation

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Farnesoid X receptor is essential for normal glucose homeostasis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Plasma bile acids are not associated with energy metabolism in humans

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Hepatic glucose-6-phosphatase flux and glucose phosphorylation, cycling, irreversible disposal, and net balance in vivo in rats. Measurement using the secreted glucuronate technique.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Whole-body glycolysis measured by the deuterated-glucose disposal test correlates highly with insulin resistance in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Quantification of hepatic carbohydrate metabolism in conscious mice using serial blood and urine spots

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Measurement of de novo hepatic lipogenesis in humans using stable isotopes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Contribution of newly synthesized cholesterol to rat plasma and bile determined by mass isotopomer distribution analysis: bile-salt flux promotes secretion of newly synthesized cholesterol into bile

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Gluconeogenesis and intrahepatic triose phosphate flux in response to fasting or substrate loads. Application of the mass isotopomer distribution analysis technique with testing of assumptions and potential problems

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Effect of dietary energy restriction on glucose production and substrate utilization in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Correct homeostasis model assessment (HOMA) evaluation uses the computer program

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker diabetic fatty rats

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Glycoconjugates as noninvasive probes of intrahepatic metabolism: pathways of glucose entry into compartmentalized hepatic UDP-glucose pools during glycogen accumulation

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

The glucose paradox. Is glucose a substrate for liver metabolism?

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

An increased flux through the glucose 6-phosphate pool in enterocytes delays glucose absorption in Fxr-/- mice

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Mechanism by which metformin reduces glucose production in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2382-3

21 January 2018

Chronic effect of oral cholestyramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/22134839

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-fat, high-carbohydrate and high-fat, low-carbohydrate diets decrease primary bile acid synthesis in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/22134839

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glucose uptake and production during the oral glucose tolerance test

1 reference

https://pubmed.ncbi.nlm.nih.gov/22134839

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of cholestyramine on the elimination of cholesterol as bile acids in patients with hyperlipoproteinaemia type II and IV

1 reference

https://pubmed.ncbi.nlm.nih.gov/22134839

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism

1 reference

https://pubmed.ncbi.nlm.nih.gov/22134839

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measurement of endogenous synthesis of plasma cholesterol in rats and humans using MIDA.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22134839

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mass isotopomer distribution analysis at eight years: theoretical, analytic, and experimental considerations

1 reference

https://pubmed.ncbi.nlm.nih.gov/22134839

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-011-2382-3

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22134839

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22134839

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51364519&oldid=1411436341"